Argos fully enrolls its trial to test a cancer therapy

Argos is developing a therapy to treat metastatic renal cell carcinoma (mRCC) and hit the enrollment goal of 450 randomized patients. This is a Phase 3 trial, meaning it is one of the last major steps a drug developer takes before submitting an application with the U.S. Food and Drug Administration.07/16/2015
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news

Related Links:

AbstractImmunotherapy has become the fourth cancer therapy after surgery, chemotherapy, and radiotherapy. In particular, immune checkpoint inhibitors are proved to be unprecedentedly in increasing the overall survival rates of patients with refractory cancers, such as advanced melanoma, non-small cell lung cancer, and renal cell carcinoma. However, inhibitor therapies are only effective in a small proportion of patients with problems, such as side effects and high costs. Therefore, doctors urgently need reliable predictive biomarkers for checkpoint inhibitor therapies to choose the optimal therapies. Here, we review the bi...
Source: Frontiers of Medicine - Category: General Medicine Source Type: research
Authors: Pawlik A, Machaj F, Rosik J, Szostak B Abstract INTRODUCTION: In cancer, the immune response to tumor antigens is often suppressed by inhibitors and ligands. Checkpoint blockade, considered one of the most promising frontiers for anti-cancer therapy, aims to stimulate the immune anti-cancer response. Agents such as cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) inhibitors offer prolonged survival with manageable side effects. Areas covered: We summarize the recent clinical successes of CTLA-4 inhibitors and place a strong emphasis on those in early phase clinical trials, often in combination with oth...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
We present a comprehensive knowledge of immune therapy through PD-1/PD-L1 blockade that argues how efficient the process is, in colon cancer carcinoma. In this review, we discuss the responsiveness of immunotherapy on PD-1/PD-L1 blockade and various tactics for overcoming weak responses to these checkpoint inhibitors in CRC. More research using controlled trials is required to enable new discoveries to provide continued success with immune-based therapies and grounds for optimism about the future of CRC patients.Graphical abstractThe mechanism of interaction between PD-1+ T-cells and PD-L1/2+ tumor cells.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
We present a comprehensive knowledge of immune therapy through PD-1/PD-L1 blockade that argues how efficient the process is, in colon cancer carcinoma. In this review, we discuss the responsiveness of immunotherapy on PD-1/PD-L1 blockade and various tactics for overcoming weak responses to these checkpoint inhibitors in CRC. More research using controlled trials is required to enable new discoveries to provide continued success with immune-based therapies and grounds for optimism about the future of CRC patients. PMID: 30522017 [PubMed - as supplied by publisher]
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Tags: Biomed Pharmacother Source Type: research
Publication date: February 2019Source: Biomedical Signal Processing and Control, Volume 48Author(s): Francisco F. Teles, João M. LemosAbstractDuring the last years several clinical decision support systems have been developed, some of which clearly improved the results obtained with standard clinical practice. However, this kind of decision computing process has not been quite explored in cancer treatment. In this work a control system that designs an optimal therapy based on adaptive control methods, aiming to allow the eradication of a metastatic renal cell carcinoma as quickly and efficiently as possible, and wit...
Source: Biomedical Signal Processing and Control - Category: Biomedical Science Source Type: research
ConclusionsThis case series represents the first description of potential skeletal adverse effects related to immune checkpoint inhibitors. These findings are important for providers caring for patients who experience musculoskeletal symptoms and may merit additional evaluation.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Abstract The combination of biologically active compounds and nanomaterials in biomedicine field is growing rapidly and provided excellent forecasts for the progress of facile non-invasive approaches for the diagnosis of cancer therapy. In this present study, we demonstrated that as-prepared gallic acid (GA) coated reduced graphene oxide (rGO) combined with radiofrequency (RF) ablation has facilitated for the treatment of human renal epithelial cancer (A-489) cells without disturbing the renal proximal epithelial (HK-2) cells. The successful biofabrication of GA onto the rGO nanostructure has been elaborated with ...
Source: Appl Human Sci - Category: Physiology Authors: Tags: Mater Sci Eng C Mater Biol Appl Source Type: research
CONCLUSIONS: P3H4 suppressed the development of renal carcinoma through upregulating miR-1a and miR-13a, which provides fundamental leads for the future anti-cancer therapy. PMID: 30178839 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Publication date: 1 December 2018Source: Materials Science and Engineering: C, Volume 93Author(s): Zhengyao Jiang, Hailong Jin, Shu Sun, Changqing Chen, Jie Zhang, Zefeng Guo, Xiaoyou LiuAbstractThe combination of biologically active compounds and nanomaterials in biomedicine field is growing rapidly and provided excellent forecasts for the progress of facile non-invasive approaches for the diagnosis of cancer therapy. In this present study, we demonstrated that as-prepared gallic acid (GA) coated reduced graphene oxide (rGO) combined with radiofrequency (RF) ablation has facilitated for the treatment of human renal epithe...
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
Cancer treatment has been transformed by the use of monoclonal antibodies (mAbs) that block immune inhibitory ligands CTLA-4 and PD-1, known as immune checkpoint inhibitors (CPIs). With these options for treatment of cancers that are resistant to conventional cancer therapies, the life expectancy of patients with melanoma, lung cancer, renal cell carcinoma, and other cancers, has shown significant improvement. However, according to the journal Diabetes, some patients experience adverse effects. One percent of patients treated with anti –PD-1 or –PD-L1 CPIs develop diabetes.08/22/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Therapy | Carcinoma | Food and Drug Administration (FDA) | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology